What happened
Novo Nordisk announced that Ozempic tablets would reach U.S. pharmacies beginning May 4, 2026. The daily product contains semaglutide. Its initiation strength is 1.5 mg; additional tablets contain 4 mg or 9 mg. The manufacturer said distribution would extend to more than 70,000 pharmacies.
The FDA prescribing information places this product in diabetes care. Ozempic tablets are used with diet and exercise to improve blood glucose in adults with type 2 diabetes. They are also indicated to reduce major cardiovascular events in adults who have type 2 diabetes and are at high risk for those events. The 1.5 mg dose is used for initiation and is not an effective maintenance dose for glucose control.
This formulation updates the oral semaglutide product formerly marketed in the United States as Rybelsus. The old and new tablet strengths are not interchangeable milligram for milligram. A person already taking Rybelsus should not calculate a replacement dose or switch products without the prescriber and pharmacist.
Ozempic tablets must be taken on an empty stomach after an overnight fast of at least eight hours. The tablet is swallowed whole with up to four ounces of water. Food, beverages, and other oral medicines should wait at least 30 minutes. These instructions affect absorption and are part of the approved dosing routine.
What it means
The launch gives adults with type 2 diabetes another way to take semaglutide without a weekly injection. Route is only one part of the decision. A clinician still needs to consider glucose goals, cardiovascular history, other medicines, kidney function, eye history, gastrointestinal symptoms, contraindications, cost, and whether the fasting routine is workable.
The manufacturer announced insurance and self-pay offers at launch. Those figures are program terms rather than a guaranteed price. Eligibility, exclusions, pharmacy participation, and the amount paid can change, so readers should verify current terms before relying on a quoted cost.
What it does not mean
This launch is not an approval of Ozempic tablets for obesity treatment. Ozempic tablets carry type 2 diabetes and cardiovascular-risk indications. Wegovy is the semaglutide brand with a U.S. weight-management indication, and its oral product uses a different maintenance strength and label.
The product is not automatically easier to use or tolerate than an injection. Nausea, vomiting, diarrhea, abdominal pain, and other adverse reactions can occur. The label also includes important warnings and contraindications that require individual review.
Availability at many pharmacies does not establish coverage or suitability. Do not split tablets, improvise a dose conversion, use the initiation dose as long-term therapy, or change from Rybelsus or injectable Ozempic without professional guidance.
Educational information only. This brief is not medical advice. Do not start, stop, or change treatment based on it.
How this brief was reported
Obesity Treatment News is a BariatricPal publication. We review linked source material, explain what changed, and state what the evidence does not establish.
Editorial standards, corrections, and commerce disclosure · About BariatricPal · About the brief author · Contact BariatricPal